On February 17, 2026, Connecticut-based Braidwell disclosed a new position in Centessa Pharmaceuticals (NASDAQ:CNTA), acquiring 2,188,320 shares in an estimated $54.73 million trade. What happened In a new U.S. Securities and Exchange Commission (SEC) filing released February 17, 2026 (link), Braidwell disclosed the purchase of 2,188,320 shares of Centessa. The net position change for the quarter was $54.73 million, reflecting the new holding’s quarter-end valuation. What else to know The new stake re ...

New York, New York--(Newsfile Corp. - February 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contin ...

Company Overview - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor aimed at treating cardiovascular risk and retinal diseases [3] - BioAge is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs that leverage insights from human longevity data [3] Upcoming Events - BioAge will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [1] - CEO Kristen Fortney and CFO Dov Goldstein will participate in a fireside chat and one-on-one meetings during the conference [2] - A live webcast of the presentation will be available, with replays accessible on the company's investor website for 30 days post-event [2] Clinical Development - A Phase 1 SAD/MAD trial of BGE-102 is currently underway, with topline data, including additional MAD cohorts, expected in the first half of 2026 [3]

Conquering Cancer with Data Q4 2025 & Full Year 2025 Earnings Call February 19, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance ...

Prothena Fourth Quarter and Year-End 2025 Financial Results 4Q and FY25 Earnings Call Agenda | Welcome | Mark Johnson Vice President, Head of Investor Relations | | --- | --- | | Opening Remarks | Gene Kinney, Ph.D. President and CEO | | Clinical Programs | Chad Swanson, Ph.D. Chief Development Officer | | Preclinical Programs | Philip Dolan, Ph.D. Vice President, Head of Discovery Research | | Financial Results | Tran Nguyen Chief Strategy Officer and Chief Financial Officer | | Closing Remarks | Gene Kinn ...

10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference [Accessibility Statement] Skip NavigationPLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- [10x Genomics, Inc.](Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m. Eastern Time.Interested parties may access a live webcast of the fireside chat on the "I ...

Core Viewpoint - Nautilus Biotechnology, Inc. is participating in the TD Cowen 46 Annual Health Care Conference, highlighting its role in the life sciences sector focused on protein analysis [1]. Company Overview - Nautilus Biotechnology, Inc. is a development stage life sciences company headquartered in Seattle, Washington, with research and development operations in San Carlos, California [3]. - The company aims to create a platform technology for quantifying and understanding the complexity of the proteome, with a mission to democratize access to proteomics and advance human health and medicine [3]. Event Participation - Management of Nautilus is scheduled for a fireside chat on March 2, 2026, at 10:30 a.m. Eastern Time, which will be accessible via a live and archived webcast on the company's website [2].

Tyra Biosciences to Participate in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationCARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:36th Annual Oppenheimer Life Sciences Healthcare ConferenceFormat: Vi ...

Core Viewpoint - The session features Cullinan Therapeutics' leadership, highlighting the company's focus on oncology and its strategic direction in the biotech sector [1] Company Overview - Cullinan Therapeutics is represented by CEO Nadim Ahmed and CMO Jeff Jones during the Citi's Virtual Oncology Leadership Summit [1] Industry Context - The event is part of Citi's initiative to engage with key players in the oncology field, reflecting the growing importance of biotech in addressing cancer treatment [1]

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study Strengthened the balance ...